Psychedelics Today8 Dec 2016

Gabby Agin-Liebes - Can Psilocybin Help Ease Anxiety & Depression for Those Who Are Facing Death?

Download It has been a big week for psychedelic research. Psilocybin and MDMA have made national headlines. The New York Times article, "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients," highlights the recent win for MAPS in regards to their MDMA-assisted psychotherapy research. The FDA has given MAPS the green light to pursue phase 3 research for MDMA-assisted psychotherapy for post-traumatic stress disorder. The New York Times also highlights the recent publications of psilocybin research in the article, "A Dose of a Hallucinogen from a 'Magic Mushroom,' and Then Lasting Peace." Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating: At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. (http://m.jop.sagepub.com/content/30/12/1165.full) In this episode, Joe and Kyle chat with, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology. During the conversation, we get into topics about the recent publication:

Formation of the NYU study
Gabby's role in the study
How volunteers were selected
Inclusion and admission criteria
Study results
Can psilocybin help those who are facing death?
Mystical experiences facilitating and mediating change in depression and anxiety
Current research that Gabby is part of and co-leading
How to get involved in the psychedelic field
Dreams and visions for the future of psychedelics and psychedelic research

About Gabrielle Agin-Liebes: Ms. Agin-Liebes is completing her training toward a PhD in clinical psychology at Palo Alto University. She is a member of PAU's Early Intervention Clinic clinical research laboratory, which provides and evaluates evidence-based treatments to prevent trauma-related problems in recently traumatized individuals. As part of this research laboratory, Ms. Agin-Liebes is examining the effects of trait self-compassion on trauma-related guilt cognitions. Through a supplemental practicum, Gabrielle is training toward a teacher certification in insight oriented mindfulness meditation through the Inner Resources Center at Palo Alto University. Ms. Agin-Liebes' other research focuses on novel and progressive psychotherapies for a variety of clinical indications, with areas of specialty in anxiety, depressive and traumatic stress disorders precipitated by life threatening illnesses. Through the University of California San Francisco (UCSF) Ms. Agin-Liebes is co-leading the qualitative investigation of a pilot study examining the safety and feasibility of Psilocybin-Assisted Supportive-Expressive Group Psychotherapy for demoralization and existential distress in older individuals living with HIV. Prior to beginning her graduate studies, Gabrielle served as Project Manager of the NYU School of Medicine (NYUSoM) Psychedelic Research Laboratory led by Stephen Ross MD in the Department of Psychiatry, where she oversaw the day-to-day operations of trials exploring psilocybin as a treatment for existential distress in cancer patients, and ketamine as a rapidly-acting antidepressant in Emergency Department patients, Through the NYU School of Medicine lab, she has received funding to investigate the qualitative experiences of participants undergoing psilocybin treatment for alcohol dependence and is helping to design a qualitative trial of religious leaders receiving psilocybin at NYUSoM and Johns Hopkins University (JHU). Ms. Agin-Liebes' other research interests include the role of self-compassion in addiction recovery and the therapeutic applications of meditation and mindfulness.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(774)

PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture

Denver mushroom decriminalization changed the national conversation around psilocybin access, personal use, and grassroots psychedelic reform. In this episode of Psychedelics Today, Joe Moore speaks w...

11 Maj 1h 43min

PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium

Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Center and Tasia Poinsatte of Healing Advocacy Fund. They join Joe Moore to discuss t...

8 Maj 54min

PT 654 - Erica Rex - Seeing What Is There

Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore to discuss her book Seeing What Is There: My Search for Sanity in the Psychedelic E...

23 Apr 1h 20min

PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy

ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist ...

16 Apr 1h 19min

PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow

Dr. Esme Dark joins Kyle Buller for a conversation on psychedelic therapy, somatic psychotherapy, and shadow work. Based in Australia, Dark is a clinical psychologist, somatic psychotherapist, and psy...

25 Mars 1h 14min

PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

MAPS co-executive directors Betty Aldworth and Ismail Ali join Psychedelics Today to talk about leading one of the most visible organizations in the psychedelic field during a period of transition. Th...

19 Mars 1h 22min

PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape

Jen Davenport joins Psychedelics Today to interview co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to engage with p...

9 Mars 1h 6min

PT 649 - Melissa Lavasani and Jay Kopelman

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization...

19 Feb 1h 10min